UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-31812 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 58-2301143 (State or other jurisdiction o ...

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q2 2019 Earnings Conference Call August 7, 2019 10:30 AM ET Company Participants Arthur Przybyl - President, CEO & Director Stephen Carey - CFO & VP of Finance Conference Call Participants Elliot Wilbur - Raymond James & Associates Brandon Folkes - Cantor Fitzgerald & Co. Operator Good morning, everyone, and welcome to ANI's Second Quarter 2019 Earnings Call. [Operator Instructions]. Please note, this call may be recorded. It is now my pleasure to turn today's program ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-31812 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 58-2301143 (State or other jurisdiction of inc ...

ANI Pharmaceuticals Inc. (NASDAQ:ANIP) Q1 2019 Earnings Conference Call May 9, 2019 10:30 AM ET Company Participants Arthur Przybyl - President and Chief Executive Officer Stephen Carey - Chief Financial Officer Conference Call Participants Lucas Lee - Raymond James Dewey Steadman - Canaccord Brandon Folkes - Cantor Fitzgerald Operator Good morning, everyone, and welcome to ANI's First Quarter 2019 Earnings Call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-31812 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 58-2301143 (State or other jurisdiction of in ...

ANI Pharmaceuticals Inc (NASDAQ:ANIP) Q4 2018 Earnings Conference Call February 27, 2019 10:30 AM ET Company Participants Arthur Przybyl - President and Chief Executive Officer Stephen Carey - Chief Financial Officer Conference Call Participants Elliot Wilbur - Raymond James Dewey Steadman - Canaccord Brandon Folkes - Cantor Fitzgerald Operator Good morning, everyone, and welcome to ANI's Fourth Quarter 2018 Earnings Call. At this time, all participants are in a listen-only mode. Later, we will have the opp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______. Commission file number 001-31812 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 58-2301143 (State or other jurisdic ...